RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 103 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $142,132,294 | +37.6% | 6,199,882 | -1.0% | 0.00% | +33.3% |
| Q2 2023 | $103,309,935 | +53.2% | 6,265,005 | +65.7% | 0.00% | +50.0% |
| Q1 2023 | $67,442,767 | -37.8% | 3,780,599 | +1.5% | 0.00% | -33.3% |
| Q4 2022 | $108,434,552 | +25.1% | 3,723,714 | +5.3% | 0.00% | 0.0% |
| Q3 2022 | $86,667,000 | +1673.4% | 3,537,499 | +200.4% | 0.00% | – |
| Q2 2022 | $4,887,000 | -87.1% | 1,177,575 | -64.1% | 0.00% | -100.0% |
| Q1 2022 | $37,833,000 | +13.9% | 3,284,105 | -1.3% | 0.00% | 0.0% |
| Q4 2021 | $33,213,000 | -24.4% | 3,328,061 | -1.0% | 0.00% | 0.0% |
| Q3 2021 | $43,907,000 | -32.8% | 3,361,986 | +0.8% | 0.00% | -50.0% |
| Q2 2021 | $65,311,000 | -2.4% | 3,335,661 | +6.1% | 0.00% | 0.0% |
| Q1 2021 | $66,905,000 | -17.6% | 3,145,360 | +15.2% | 0.00% | -33.3% |
| Q4 2020 | $81,195,000 | +42.0% | 2,731,106 | +3.5% | 0.00% | +50.0% |
| Q3 2020 | $57,196,000 | -8.3% | 2,639,352 | -5.6% | 0.00% | 0.0% |
| Q2 2020 | $62,347,000 | +64.0% | 2,795,841 | +12.0% | 0.00% | 0.0% |
| Q1 2020 | $38,006,000 | -35.2% | 2,497,126 | -2.3% | 0.00% | 0.0% |
| Q4 2019 | $58,657,000 | +40.1% | 2,554,766 | +31.7% | 0.00% | 0.0% |
| Q3 2019 | $41,867,000 | -0.3% | 1,939,151 | +1.6% | 0.00% | 0.0% |
| Q2 2019 | $41,976,000 | +0.2% | 1,908,058 | +24.9% | 0.00% | 0.0% |
| Q1 2019 | $41,881,000 | +0.2% | 1,527,973 | -1.7% | 0.00% | 0.0% |
| Q4 2018 | $41,790,000 | +25.5% | 1,554,706 | +36.2% | 0.00% | +100.0% |
| Q3 2018 | $33,297,000 | +42.5% | 1,141,503 | +52.7% | 0.00% | 0.0% |
| Q2 2018 | $23,371,000 | +204.4% | 747,669 | +93.8% | 0.00% | – |
| Q1 2018 | $7,678,000 | -26.6% | 385,802 | +7.1% | 0.00% | – |
| Q4 2017 | $10,465,000 | – | 360,071 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |